Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study (ASPEN)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with moderate to severe aortic stenosis (AVA < 1.5 cm2)
- Left ventricular hypertrophy
- Diastolic dysfunction as evidenced by tissue Doppler e' (average of septal and lateral) ≤ 7 cm/s
- EF ≥ 50%
- None or minimal symptoms related to aortic stenosis (NYHA ≤ 2)
- The subject and treating physician are not planning on a valve replacement procedure to occur during the next 6 months
- Ambulatory
- Normal sinus rhythm
- 18 years of age and older
- Able and willing to comply with all the requirements for the study
Exclusion Criteria:
- Need for ongoing nitrate medications
- SBP < 110mmHg or MAP < 75mmHg
- Moderately severe or severe mitral regurgitation
- Moderately severe or severe aortic regurgitation
- Contraindication to MRI
- Creatinine clearance < 30 mL/min
- Cirrhosis
- Pulmonary fibrosis
- Increased risk of priapism
- Retinal or optic nerve problems or unexplained visual disturbance
- If a subject requires ongoing use of an alpha antagonist typically used for benign prostatic hyperplasia (BPH) (prazosin, terazosin, doxazosin, or tamsulosin), SBP < 120 mmHg or MAP < 80 mmHg is excluded
- Need for ongoing use of a potent CYP3A inhibitor or inducer (ritonavir, ketoconazole, itraconazole, rifampin)
- Current or recent (≤ 30 days) acute coronary syndrome
- O2 sat < 90% on room air
- Females that are pregnant or believe they may be pregnant
- Any condition which the PI determines will place the subject at increased risk or is likely to yield unreliable data
- Unwilling to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Tadalafil in Diabetic Cohort
|
Active drug will be encapsulated to look identical to the placebo pill.
Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months).
Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily.
If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
Other Names:
|
|
Placebo Comparator: Placebo in Diabetic Cohort
|
The placebo pill will be encapsulated to look identical to the active drug pill.
Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months).
Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily.
If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
|
|
Active Comparator: Tadalafil in Non-Diabetic Cohort
|
Active drug will be encapsulated to look identical to the placebo pill.
Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months).
Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily.
If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
Other Names:
|
|
Placebo Comparator: Placebo in Non-Diabetic Cohort
|
The placebo pill will be encapsulated to look identical to the active drug pill.
Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months).
Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily.
If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diastolic Function as Measured by Tissue Doppler e'
Time Frame: Baseline, 12 weeks, and 6 months
|
Measurement of e' (average of septal and lateral) on echo at each of the time points specified.
|
Baseline, 12 weeks, and 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Myocardial Fibrosis (ECV) on MRI
Time Frame: 6 months
|
6 months
|
|
|
Change in Other Echocardiographic Indices of Diastolic Function
Time Frame: 12 weeks and 6 months
|
E/e' and deceleration time
|
12 weeks and 6 months
|
|
Safety and Tolerability
Time Frame: 6 and 12 weeks and 6 months
|
The following with be reported - frequency of the following: hypotension (SBP < 90 mmHg), symptomatic hypotension (symptoms of presyncope or syncope associated with SBP <90), syncope, hospitalization for a cardiac reason, myocardial infarction, new onset or worsening heart failure, and new sustained arrhythmia requiring intervention
|
6 and 12 weeks and 6 months
|
|
Change in Indices of Systolic Function
Time Frame: 12 weeks and 6 months
|
Stroke volume, EF, LV twist, and stress-corrected midwall shortening by echo and 3D multiparametric strain and EF by MRI
|
12 weeks and 6 months
|
|
Change in LV Hypertrophic Remodeling
Time Frame: 12 weeks and 6 months
|
Relative wall thickness, LV chamber dimensions, and wall thickness
|
12 weeks and 6 months
|
|
Change in Novel Echocardiographic Indices of Diastolic Function
Time Frame: 12 weeks and 6 months
|
LV stiffness, viscoelasticity, and a load independent index of diastolic filling
|
12 weeks and 6 months
|
|
Change in 6 Minute Walk Distance
Time Frame: 6 and 12 weeks and 6 months
|
6 and 12 weeks and 6 months
|
|
|
Change in Circulating Neurohormonal Markers
Time Frame: 6 and 12 weeks and 6 months
|
BNP and systemic markers of collagen turnover and oxidative stress
|
6 and 12 weeks and 6 months
|
|
Change in Quality of Life
Time Frame: 6 and 12 weeks and 6 months
|
Assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ)
|
6 and 12 weeks and 6 months
|
|
Change in Pulmonary Artery Pressure and Pulmonary Vascular Resistance as Assessed by Echo
Time Frame: 12 weeks and 6 months
|
12 weeks and 6 months
|
|
|
Change in Systemic Blood Pressure
Time Frame: 6 and 12 weeks and 6 months
|
6 and 12 weeks and 6 months
|
|
|
Change in RV Function
Time Frame: 12 weeks and 6 months
|
TAPSE, s' tissue Doppler, and Tei index
|
12 weeks and 6 months
|
|
Change in AS Severity
Time Frame: 12 weeks and 6 months
|
Aortic valve area, transvalvular pressure gradients
|
12 weeks and 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brian R. Lindman, MD, MSCI, Washington University School of Medicine
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Pathological Conditions, Anatomical
- Aortic Valve Disease
- Heart Valve Diseases
- Ventricular Outflow Obstruction
- Aortic Valve Stenosis
- Hypertrophy
- Constriction, Pathologic
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Urological Agents
- Enzyme Inhibitors
- Phosphodiesterase Inhibitors
- Phosphodiesterase 5 Inhibitors
- Tadalafil
Other Study ID Numbers
Other Study ID Numbers
- 10-1334b
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.